Savolitinib Completes Enrolment for Phase II Clinical Trial in Papillary Renal Cell Carcinoma
Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that Hutchison MediPharma Limited ("HMP"), its drug R&D subsidiary, and AstraZeneca AB (pu...




